Efficacy and Safety of Dry Powder Antibiotics : A Narrative Review
de la Rosa Carrillo, David (Institut d'Investigació Biomèdica Sant Pau)
Suarez-Cuartin, Guillermo (Hospital Universitari de Bellvitge)
Sibila, Oriol (Hospital Clínic i Provincial de Barcelona)
Golpe, Rafael (Hospital Universitario Lucus Augusti (Lugo))
Girón, Rosa (Hospital Universitario de la Princesa (Madrid))
Martínez-García, Miguel Ángel (Hospital Universitari i Politècnic La Fe (València))
Universitat Autònoma de Barcelona

Data:	2023
Resum:	The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Antibiotics ; Bronchiectasis ; Chronic bronchial infection ; Cystic fibrosis ; Dry powder antibiotics ; Inhalation drug ; Pseudomonas aeruginosa
Publicat a:	Journal of clinical medicine, Vol. 12 Núm. 10 (may 2023) , p. 3577, ISSN 2077-0383

DOI: 10.3390/jcm12103577
PMID: 37240682

20 p, 1.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats